| Diabetes Mellitus
Levemir vs Toujeo
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Levemir vs Toujeo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsToujeo has a higher rate of injection site reactions vs Levemir based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Toujeo but not Levemir, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Levemir
Toujeo
At A Glance
SC injection
Once or twice daily
Long-acting basal insulin analog
SC injection
Once daily
Long-acting insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus (Type 1) Approximately one-third to one-half of the total daily insulin dose SC once or twice daily in combination with rapid-acting or short-acting insulin; initial total daily dose 0.2-0.4 units/kg in insulin-naive patients.
Diabetes Mellitus (Type 2) 10 units (or 0.1-0.2 units/kg) SC once daily in the evening or divided into a twice-daily regimen in patients inadequately controlled on oral antidiabetic medications or a GLP-1 receptor agonist.
Diabetes Mellitus, Type 1 (insulin-naive) Approximately one-third to one-half of total daily insulin dose SC once daily; remainder given as short-acting insulin divided between daily meals.
Diabetes Mellitus, Type 2 (insulin-naive) 0.2 units/kg SC once daily.
Switching from once-daily long/intermediate-acting insulin Start at same unit dose as prior once-daily long-acting insulin SC once daily; monitor glucose closely during initial weeks.
Switching from twice-daily long/intermediate-acting insulin Start at 80% of total daily NPH or insulin detemir twice-daily dosage SC once daily; monitor glucose frequently.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin detemir or any excipient in LEVEMIR, including reactions such as anaphylaxis
- Active hypoglycemia episode
- Hypersensitivity to insulin glargine or any excipient in Toujeo
Adverse Reactions
Most common (>=5%) Upper respiratory tract infection, headache, pharyngitis, influenza-like illness, abdominal pain, hypoglycemia
Serious Severe hypoglycemia, anaphylaxis, generalized skin reactions, angioedema, bronchospasm, hypotension, shock, lipodystrophy, peripheral edema, hypokalemia
Postmarketing Medication errors with accidental administration of other insulins instead of LEVEMIR, localized cutaneous amyloidosis, hyperglycemia or hypoglycemia associated with injection into amyloidosis sites
Most common (>=5%) nasopharyngitis, upper respiratory tract infection, hypoglycemia
Serious severe hypoglycemia, anaphylaxis, peripheral edema, lipodystrophy, hypokalemia
Postmarketing localized cutaneous amyloidosis at injection site, hyperglycemia or hypoglycemia associated with injections into or away from amyloidosis areas
Pharmacology
Long-acting basal human insulin analog that regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production; prolonged duration of action is mediated by self-association of drug molecules at the injection site and albumin binding in the bloodstream.
Long-acting insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat, inhibiting hepatic glucose production, inhibiting lipolysis and proteolysis, and enhancing protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Levemir
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (1/12) · Qty limit (0/12)
Toujeo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Levemir
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Toujeo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Levemir
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (1/3) · Qty limit (0/3)
Toujeo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Levemir.
No savings programs available for Toujeo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LevemirView full Levemir profile
ToujeoView full Toujeo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.